实验动物黏膜相关淋巴结组织改良组织病理学评价方法研究进展  

Advance in methodology of improved pathological evaluation for mucosa-associated lymphoid tissues in experimental animals

作　　者：李珊珊[1] 李波[1] 

机构地区：[1]中国药品生物制品检定所国家药物安全评价监测中心,北京100176

出　　处：《中国新药杂志》2008年第17期1468-1469,1473,共3页Chinese Journal of New Drugs

摘　　要：近年来,世界各国药品管理机构都非常重视药物引起免疫系统损伤的毒性病理学评价。2006年,美国STP在"免疫系统常规病理学评价最佳操作指南(2005)"岗位说明的基础上,发表了"淋巴器官改良的组织病理学评价"的方法,其作为能够运用的一种工具可协助毒性病理学工作者辩识评价免疫调制作用药物。现对黏膜相关淋巴结组织的组织结构、生理功能、形态学特征、改良的组织病理学诊断要点以及评价方法进行了归纳和概括性介绍,为相关领域的科研人员提供参考。Currently, drug regulatory organizations in the world have realized the significance of histopathology evaluation in immunotoxicity. Shortly after the 2005, the ＂Society of Toxicologic Pathology （STP） Position Paper on Best Practice Guidelines for the Routine Pathology Evaluation of the immune System＂ has been published, and ＂Enhanced Histopathology of Lymphoid Tissues＂ published by STP again. These documents are the tools with higher academic value for the pathologist to assist in the identification of immunomodulatory drugs. Lymphoid tissues include lymph node, spleen, thymus, mucosa-associated lymphoid tissue and bone marrow. The article reviewed the histostructure, physiologic function, morphology characteristics, and introduced the main feature of diagnosis highlight and evaluation methods to provide some useful insights for researchers.

关 键 词：黏膜相关淋巴结组织(MALT) 改良的组织病理学评价 描述性术语 

分 类 号：R994[医药卫生—毒理学]